Enantia, selected by Neogenius as preferred partner

Set up on the basis of a strategic alliance between four pharmaceutical companies (Almirall, Esteve, Palau Pharma and Proteomika), the Neogenius project kicks off and runs for four years with a total budget of 15.4 million euros with the objective to discover and develop new painkilling medicines for patients suffering from osteoarthritis.

Enantia is selected as custom synthesis provider to support the drug discovery activities of the consortium.